<p>DAVENPORT &amp; Co LLC 在最近向美國證券交易委員會提交的 13F 表格中表示，在第三季度將其在 DexCom, Inc.（NASDAQ:DXCM - 免費報告）的持股增加了 21.5%。該公司在此期間額外購買了 15,024 股後，持有該醫療設備公司 84,967 股股票。DAVENPORT &amp; Co LLC 在 DexCom 的持股在最近一個季度末價值 5,717,000 美元。</p>
<ul>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
</ul>
<p>其他幾家機構投資者最近也增加或減少了在 DXCM 的持股。SWS Partners 在第二季度收購了 DexCom 的新股份，價值 1,661,000 美元。Baader Bank Aktiengesellschaft 在第二季度購買了價值約 393,000 美元的 DexCom 新股份。Jennison Associates LLC 在第二季度將其在 DexCom 的持股增加了 9.4%。Jennison Associates LLC 現在持有該醫療設備公司 11,517,546 股股票，價值 1,005,367,000 美元，此前在此期間又購買了 994,300 股。Mn Services Vermogensbeheer B.V. 在第二季度將其在 DexCom 的持股增加了 4.9%。Mn Services Vermogensbeheer B.V. 現在持有該醫療設備公司 146,600 股股票，價值 12,797,000 美元，此前在此期間又購買了 6,800 股。最後，Assenagon Asset Management S.A. 在第二季度將其在 DexCom 的持股增加了 85.7%。Assenagon Asset Management S.A. 現在持有該醫療設備公司 1,208,255 股股票，價值 105,469,000 美元，此前在上個季度又購買了 557,576 股。機構投資者和對沖基金持有該公司 97.75% 的股票。</p>
<h2>DexCom 股價上漲 0.4%</h2>
<p>DXCM 的股票在週五開盤價為 67.15 美元。DexCom, Inc. 的 1 年最低價為 54.11 美元，1 年最高價為 93.25 美元。該公司的債務與股本比率為 0.45，流動比率為 1.56，速動比率為 1.38。該公司的 50 日簡單移動平均線為 64.05 美元，200 日簡單移動平均線為 73.31 美元。該股票的市值為 261.9 億美元，市盈率為 37.30，市盈增長比率為 1.45，貝塔值為 1.51。</p>
<ul>
<li>最具性價比？兩隻上漲潛力超過 30% 的便宜股票</li>
</ul>
<p>DexCom（NASDAQ:DXCM - 獲取免費報告）最近於 10 月 30 日星期四發佈了季度財報。該醫療設備公司報告本季度每股收益為 0.61 美元，超出分析師一致預期的 0.57 美元，超出幅度為 0.04 美元。DexCom 的股本回報率為 30.65%，淨利潤率為 15.96%。該公司本季度的收入為 12.1 億美元，而分析師預期為 11.8 億美元。在去年同期，該公司每股收益為 0.45 美元。與去年同期相比，該公司的季度收入增長了 21.6%。股票分析師預測 DexCom, Inc. 本財年的每股收益將達到 2.03 美元。</p>
<h2>DexCom 內部活動</h2>
<p>在其他新聞中，首席運營官 Jacob Steven Leach 於 11 月 10 日星期一購買了該公司 18,200 股股票。每股平均購買價格為 55.04 美元，總交易額為 1,001,728.00 美元。交易完成後，首席運營官持有該公司 331,697 股股票，價值 18,256,602.88 美元。此次交易使其持股增加了 5.81%。該交易已在美國證券交易委員會的備案中披露，具體信息可在此鏈接查看。此外，董事 Bridgette P. Heller 於 11 月 12 日星期三出售了 1,012 股 DexCom 股票。該股票以每股平均價格 58.07 美元出售，總交易額為 58,766.84 美元。交易完成後，該董事直接持有該公司 27,031 股股票，價值 1,569,690.17 美元。此次交易使其持股減少了 3.61%。有關此次出售的更多細節可在官方 SEC 披露中找到。在上個季度，內部人士出售了價值 448,177 美元的 7,866 股公司股票。內部人士持有該股票的 0.32%。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>DexCom 股票：盈利超預期和新市場準入推動看漲預期</li>
</ul>
<p>DXCM 已成為幾份研究分析師報告的主題。Oppenheimer 在 9 月 8 日星期一的研究報告中將 DexCom 的評級從 “跑贏大盤” 下調至 “市場表現”。Stifel Nicolaus 於 10 月 21 日星期二開始對 DexCom 的股票進行覆蓋。他們給予了 “買入” 評級，並設定了 85.00 美元的目標價。Cowen 在 10 月 24 日星期五的研究報告中重申了對 DexCom 股票的 “買入” 評級。華爾街 Zen 在 11 月 16 日星期日的報告中將 DexCom 的股票評級從 “強力買入” 下調至 “買入”。最後，摩根士丹利在 12 月 2 日星期二將 DexCom 的評級從 “持平” 上調至 “增持”，並將其目標價從 63.00 美元提高至 75.00 美元。三位股票研究分析師對該股票給予了強烈買入評級，十九位給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，共識目標價為 86.61 美元。</p>
<p><strong>獲取我們最新的 DXCM 股票分析</strong></p>
<h2>DexCom 公司簡介</h2>
<p>（免費報告）</p>
<p>DexCom, Inc. 是一家醫療設備公司，開發、製造和分銷用於糖尿病患者的連續血糖監測（CGM）系統。其產品旨在提供近實時的血糖讀數、趨勢信息和警報，以幫助患者和臨牀醫生管理胰島素劑量，減少低血糖和高血糖。該公司的產品結合了可穿戴的血糖傳感器、無線發射器和軟件應用程序，將數據傳輸到智能手機、專用接收器和基於雲的平台進行遠程監控。</p>
<p>德康醫療成立於 1999 年，總部位於加利福尼亞州聖地亞哥，專注於推進連續血糖監測（CGM）技術，並擴大其在傳統胰島素依賴人羣之外的臨牀應用。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票比德康醫療更好</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備迎戰</li>
<li>在 1 月 1 日之前投資 1000 美元於這隻股票 [不是 NVDA]</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33000% 暴漲？</li>
</ul>
<p><strong>想看看其他對 DXCM 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取德康醫療（NASDAQ:DXCM - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元於德康醫療嗎？</h2>
<p>在考慮德康醫療之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而德康醫療並不在名單上。</p>
<p>雖然德康醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

德康醫療

<p>根據 DAVENPORT & Co LLC 最近向美國證券交易委員會提交的 13F 表格，第三季度其在 DexCom, Inc.（NASDAQ:DXCM - 免費報告）股票中的持股增加了 21.5%</p>

<p>DAVENPORT &amp; Co LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 84,967 shares of the medical device company's stock after buying an additional 15,024 shares during the period. DAVENPORT &amp; Co LLC's holdings in DexCom were worth $5,717,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>DAVENPORT &amp; Co LLC 在最近向美國證券交易委員會提交的 13F 表格中表示，在第三季度將其在 DexCom, Inc.（NASDAQ:DXCM - 免費報告）的持股增加了 21.5%。該公司在此期間額外購買了 15,024 股後，持有該醫療設備公司 84,967 股股票。DAVENPORT &amp; Co LLC 在 DexCom 的持股在最近一個季度末價值 5,717,000 美元。</p>
</div><ul>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in DXCM. SWS Partners acquired a new stake in shares of DexCom in the 2nd quarter worth $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in DexCom in the 2nd quarter valued at approximately $393,000. Jennison Associates LLC increased its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company's stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period. Mn Services Vermogensbeheer B.V. increased its position in DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company's stock worth $12,797,000 after purchasing an additional 6,800 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company's stock valued at $105,469,000 after buying an additional 557,576 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也增加或減少了在 DXCM 的持股。SWS Partners 在第二季度收購了 DexCom 的新股份，價值 1,661,000 美元。Baader Bank Aktiengesellschaft 在第二季度購買了價值約 393,000 美元的 DexCom 新股份。Jennison Associates LLC 在第二季度將其在 DexCom 的持股增加了 9.4%。Jennison Associates LLC 現在持有該醫療設備公司 11,517,546 股股票，價值 1,005,367,000 美元，此前在此期間又購買了 994,300 股。Mn Services Vermogensbeheer B.V. 在第二季度將其在 DexCom 的持股增加了 4.9%。Mn Services Vermogensbeheer B.V. 現在持有該醫療設備公司 146,600 股股票，價值 12,797,000 美元，此前在此期間又購買了 6,800 股。最後，Assenagon Asset Management S.A. 在第二季度將其在 DexCom 的持股增加了 85.7%。Assenagon Asset Management S.A. 現在持有該醫療設備公司 1,208,255 股股票，價值 105,469,000 美元，此前在上個季度又購買了 557,576 股。機構投資者和對沖基金持有該公司 97.75% 的股票。</p>
</div><h2>DexCom Trading Up 0.4%</h2>
<div class="lb-trans"><h2>DexCom 股價上漲 0.4%</h2>
</div><p>Shares of DXCM opened at $67.15 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $64.05 and a 200-day simple moving average of $73.31. The stock has a market cap of $26.19 billion, a price-to-earnings ratio of 37.30, a price-to-earnings-growth ratio of 1.45 and a beta of 1.51.</p>
<div class="lb-trans"><p>DXCM 的股票在週五開盤價為 67.15 美元。DexCom, Inc. 的 1 年最低價為 54.11 美元，1 年最高價為 93.25 美元。該公司的債務與股本比率為 0.45，流動比率為 1.56，速動比率為 1.38。該公司的 50 日簡單移動平均線為 64.05 美元，200 日簡單移動平均線為 73.31 美元。該股票的市值為 261.9 億美元，市盈率為 37.30，市盈增長比率為 1.45，貝塔值為 1.51。</p>
</div><ul>
<li>Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>最具性價比？兩隻上漲潛力超過 30% 的便宜股票</li>
</ul>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion during the quarter, compared to analysts' expectations of $1.18 billion. During the same period in the previous year, the firm posted $0.45 earnings per share. The business's revenue for the quarter was up 21.6% compared to the same quarter last year. Equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>DexCom（NASDAQ:DXCM - 獲取免費報告）最近於 10 月 30 日星期四發佈了季度財報。該醫療設備公司報告本季度每股收益為 0.61 美元，超出分析師一致預期的 0.57 美元，超出幅度為 0.04 美元。DexCom 的股本回報率為 30.65%，淨利潤率為 15.96%。該公司本季度的收入為 12.1 億美元，而分析師預期為 11.8 億美元。在去年同期，該公司每股收益為 0.45 美元。與去年同期相比，該公司的季度收入增長了 21.6%。股票分析師預測 DexCom, Inc. 本財年的每股收益將達到 2.03 美元。</p>
</div><h2>Insider Activity at DexCom</h2>
<div class="lb-trans"><h2>DexCom 內部活動</h2>
</div><p>In other news, COO Jacob Steven Leach bought 18,200 shares of the firm's stock in a transaction that occurred on Monday, November 10th. The shares were purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company's stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席運營官 Jacob Steven Leach 於 11 月 10 日星期一購買了該公司 18,200 股股票。每股平均購買價格為 55.04 美元，總交易額為 1,001,728.00 美元。交易完成後，首席運營官持有該公司 331,697 股股票，價值 18,256,602.88 美元。此次交易使其持股增加了 5.81%。該交易已在美國證券交易委員會的備案中披露，具體信息可在此鏈接查看。此外，董事 Bridgette P. Heller 於 11 月 12 日星期三出售了 1,012 股 DexCom 股票。該股票以每股平均價格 58.07 美元出售，總交易額為 58,766.84 美元。交易完成後，該董事直接持有該公司 27,031 股股票，價值 1,569,690.17 美元。此次交易使其持股減少了 3.61%。有關此次出售的更多細節可在官方 SEC 披露中找到。在上個季度，內部人士出售了價值 448,177 美元的 7,866 股公司股票。內部人士持有該股票的 0.32%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
</ul>
<div class="lb-trans"><ul>
<li>DexCom 股票：盈利超預期和新市場準入推動看漲預期</li>
</ul>
</div><p>DXCM has been the subject of several research analyst reports. Oppenheimer cut DexCom from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Monday, September 8th. Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a &#34;buy&#34; rating and a $85.00 price target for the company. Cowen reiterated a &#34;buy&#34; rating on shares of DexCom in a research note on Friday, October 24th. Wall Street Zen cut shares of DexCom from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, November 16th. Finally, Morgan Stanley raised DexCom from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their price target for the stock from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $86.61.</p>
<div class="lb-trans"><p>DXCM 已成為幾份研究分析師報告的主題。Oppenheimer 在 9 月 8 日星期一的研究報告中將 DexCom 的評級從 “跑贏大盤” 下調至 “市場表現”。Stifel Nicolaus 於 10 月 21 日星期二開始對 DexCom 的股票進行覆蓋。他們給予了 “買入” 評級，並設定了 85.00 美元的目標價。Cowen 在 10 月 24 日星期五的研究報告中重申了對 DexCom 股票的 “買入” 評級。華爾街 Zen 在 11 月 16 日星期日的報告中將 DexCom 的股票評級從 “強力買入” 下調至 “買入”。最後，摩根士丹利在 12 月 2 日星期二將 DexCom 的評級從 “持平” 上調至 “增持”，並將其目標價從 63.00 美元提高至 75.00 美元。三位股票研究分析師對該股票給予了強烈買入評級，十九位給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，共識目標價為 86.61 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on DXCM</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 DXCM 股票分析</strong></p>
</div><h2>DexCom Company Profile</h2>
<div class="lb-trans"><h2>DexCom 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.</p>
<div class="lb-trans"><p>DexCom, Inc. 是一家醫療設備公司，開發、製造和分銷用於糖尿病患者的連續血糖監測（CGM）系統。其產品旨在提供近實時的血糖讀數、趨勢信息和警報，以幫助患者和臨牀醫生管理胰島素劑量，減少低血糖和高血糖。該公司的產品結合了可穿戴的血糖傳感器、無線發射器和軟件應用程序，將數據傳輸到智能手機、專用接收器和基於雲的平台進行遠程監控。</p>
</div><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p>
<div class="lb-trans"><p>德康醫療成立於 1999 年，總部位於加利福尼亞州聖地亞哥，專注於推進連續血糖監測（CGM）技術，並擴大其在傳統胰島素依賴人羣之外的臨牀應用。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比德康醫療更好</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備迎戰</li>
<li>在 1 月 1 日之前投資 1000 美元於這隻股票 [不是 NVDA]</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33000% 暴漲？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DXCM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 DXCM 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取德康醫療（NASDAQ:DXCM - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元於德康醫療嗎？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮德康醫療之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而德康醫療並不在名單上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然德康醫療目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

DAVENPORT & Co LLC 增加了在 DexCom 公司$DXCM 的持倉